查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586049

癌症惡病質市場：治療方法、特徵和分銷管道分類 - 全球預測 2025-2030

Cancer Cachexia Market by Therapy (Combination Therapies, Corticosteroids, Progestogens), Functionality (Appetite Stimulators, Weight Loss Stabilizers), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症惡病質市場價值為20.9億美元，預計到2024年將達到22.4億美元，複合年成長率為7.53%，到2030年將達到34.8億美元。

癌症惡病質是一種複雜的症候群，其特徵是嚴重體重減輕、肌肉無力和食物攝取減少，常見於癌症患者。這種病症的定義超越了簡單的厭食症，還包括導致重大發病和死亡風險的代謝變化。作為市場研究分析師，了解這種症候群的需要是開發有效的治療方案，以改善受影響患者的生活品質和存活率。典型應用包括藥物、營養食品和支持性護理，最終用途包括醫院、癌症治療中心和家庭護理機構。癌症發生率的增加推動了市場的成長，需要更個人化和全面的治療解決方案。對安寧療護和以患者為中心的治療的日益關注正在進一步推動市場擴張。

主要市場統計
基準年[2023] 20.9億美元
預測年份 [2024] 22.4億美元
預測年份 [2030] 34.8億美元
複合年成長率（%） 7.53%

影響成長的因素包括生物技術的進步和正在進行的代謝途徑研究，為創新藥物開發提供了機會。此外，老年人口的增加，更容易罹患癌症和惡病質，也增加了市場潛力。然而，複雜的藥物開發流程、高成本和嚴格的監管要求等挑戰構成了巨大的障礙。此外，癌症惡病質的異質性受到不同癌症類型和階段的影響，使治療通訊協定的標準化變得複雜。

有機會探索結合藥物和非藥物介入的多模態治療方法。一個新興的研究領域正在闡明導致惡病質的分子機制，這可能會導致標靶治療。對個人化醫療和生物標記的關注可以帶來滿足個別患者需求的創新產品。製藥公司、研究機構和醫療保健提供者之間的合作可以促進這些發展。

在癌症研究和治療技術不斷進步的推動下，市場具有高度動態性。專注於開發綜合治療方法、改善患者營養和加強整體患者管理系統的公司將擁有競爭優勢。確定老年腫瘤學的利基市場並加強對患者惡病質管理的教育可以進一步推動成長。

市場動態：快速發展的癌症惡病質市場揭示的關鍵市場洞察

供需的動態交互作用正在改變癌症惡病質市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老年人口惡病質盛行率增加
    • 是否有適當的報銷政策
    • 改善醫療基礎設施並提高對癌症惡病質治療的認知
  • 市場限制因素
    • 治療費用上漲
  • 市場機會
    • 癌症惡病質治療技術的進展
    • 增加研發活動以發現治療方法
  • 市場挑戰
    • 執行嚴格的監管要求和更長的 FDA 批准

波特的五力：駕馭癌症惡病質市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解癌症惡病質市場的外部影響

外部宏觀環境因素在塑造癌症惡病質市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解癌症惡病質市場的競爭格局

對癌症惡病質市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣癌症惡病質市場供應商的績效評估

FPNV 定位矩陣是評估癌症惡病質市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製癌症惡病質市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對癌症惡病質市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老年人惡病質盛行率增加
      • 是否有適當的報銷政策
      • 改善醫療基礎設施並提高治療癌症惡病質的意識
    • 抑制因素
      • 治療費用高
    • 機會
      • 治療癌症惡病質的技術進展
      • 增加旨在發現治療藥物的研發活動
    • 任務
      • 執行嚴格的監管要求和長期 FDA核准
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症惡病質市場治療

  • 聯合治療
  • 皮質類固醇
  • 黃體素

第7章依功能分類的癌症惡病質市場

  • 食慾興奮劑
  • 減重穩定劑

第8章癌症惡病質市場：依通路

  • 醫院商店
  • 網路藥房
  • 零售藥房

第9章美洲癌症惡病質市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太癌症惡病質市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲癌症惡病質市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AAVogen Inc.
  • Actimed Therapeutics Ltd.
  • Aeterna Zentaris Inc.
  • Aphios Corporation
  • Artelo Biosciences Inc.
  • AVEO Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Fresenius Kabi AG
  • Green Cross Wellbeing Corporation
  • Helsinn Healthcare SA
  • INOVIO Pharmaceuticals Inc.
  • Mankind Pharma Ltd.
  • Merck & Co. Inc.
  • MetaFines Co., Ltd.
  • NeuBase Therapeutics, Inc.
  • NGM Biopharmaceuticals Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Tetra Bio-Pharma
Product Code: MRR-02026C4C92B4

The Cancer Cachexia Market was valued at USD 2.09 billion in 2023, expected to reach USD 2.24 billion in 2024, and is projected to grow at a CAGR of 7.53%, to USD 3.48 billion by 2030.

Cancer cachexia is a complex syndrome characterized by severe weight loss, muscle wasting, and reduced food intake, frequently observed in cancer patients. The condition's definition extends beyond mere anorexia, encompassing metabolic changes that lead to significant morbidity and mortality risks. As a market research analyst, the necessity for understanding this syndrome lies in developing effective treatment options to improve the quality of life and survival rates of affected patients. Key applications include pharmaceuticals, nutritional supplements, and supportive care therapies, with end-use spanning hospitals, cancer treatment centers, and home care settings. Market growth is driven by increasing cancer prevalence, demanding more personalized and comprehensive therapeutic solutions. The growing focus on palliative care and patient-centric treatment further propels the market's expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.24 billion
Forecast Year [2030] USD 3.48 billion
CAGR (%) 7.53%

Factors impacting growth include advancements in biotechnology and ongoing research into metabolic pathways, providing opportunities for innovative drug development. The growing geriatric population, susceptible to cancer and, hence, cachexia, also boosts market potential. However, challenges such as complex drug development processes, high costs, and stringent regulatory requirements pose significant barriers. Furthermore, the heterogeneity of cancer cachexia, influenced by various cancer types and stages, complicates the standardization of treatment protocols.

Opportunities exist in exploring multi-modal treatment approaches, combining pharmacological and non-pharmacological interventions. Emerging research areas include understanding molecular mechanisms driving cachexia, which could lead to targeted therapies. Emphasis on personalized medicine and biomarkers offers potential for innovative products that cater to individual patient needs. Collaborations between pharmaceutical companies, research institutions, and healthcare providers can expedite these developments.

The market's nature is highly dynamic, driven by continual advancements in cancer research and therapeutic technologies. Companies focusing on developing integrated treatment regimes, improving patient nutrition, and enhancing overall patient management systems stand to gain a competitive edge. Identifying niche markets within geriatric oncology and enhancing patient education about cachexia management can further stimulate growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Cachexia Market

The Cancer Cachexia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cachexia amongst the geriatric population
    • Presence of adequate reimbursement policies
    • Improving healthcare infrastructure and rise in awareness to treat cancer cachexia
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Technological advancements for the treatment of cancer cachexia
    • Rising number of research and development activities for the discovery of therapeutic drugs
  • Market Challenges
    • Implementation of stringent regulatory requirements and lengthy FDA approval

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Cachexia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Cachexia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Cachexia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Cachexia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Cachexia Market

A detailed market share analysis in the Cancer Cachexia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Cachexia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Cachexia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Cachexia Market

A strategic analysis of the Cancer Cachexia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Cachexia Market, highlighting leading vendors and their innovative profiles. These include AAVogen Inc., Actimed Therapeutics Ltd., Aeterna Zentaris Inc., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Fresenius Kabi AG, Green Cross Wellbeing Corporation, Helsinn Healthcare SA, INOVIO Pharmaceuticals Inc., Mankind Pharma Ltd., Merck & Co. Inc., MetaFines Co., Ltd., NeuBase Therapeutics, Inc., NGM Biopharmaceuticals Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., and Tetra Bio-Pharma.

Market Segmentation & Coverage

This research report categorizes the Cancer Cachexia Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy, market is studied across Combination Therapies, Corticosteroids, and Progestogens.
  • Based on Functionality, market is studied across Appetite Stimulators and Weight Loss Stabilizers.
  • Based on Distribution Channel, market is studied across Hospital Stores, Online Pharmacy, and Retail Pharmacy Stores.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cachexia amongst the geriatric population
      • 5.1.1.2. Presence of adequate reimbursement policies
      • 5.1.1.3. Improving healthcare infrastructure and rise in awareness to treat cancer cachexia
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements for the treatment of cancer cachexia
      • 5.1.3.2. Rising number of research and development activities for the discovery of therapeutic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Implementation of stringent regulatory requirements and lengthy FDA approval
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Cachexia Market, by Therapy

  • 6.1. Introduction
  • 6.2. Combination Therapies
  • 6.3. Corticosteroids
  • 6.4. Progestogens

7. Cancer Cachexia Market, by Functionality

  • 7.1. Introduction
  • 7.2. Appetite Stimulators
  • 7.3. Weight Loss Stabilizers

8. Cancer Cachexia Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Stores
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy Stores

9. Americas Cancer Cachexia Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Cachexia Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Cachexia Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AAVogen Inc.
  • 2. Actimed Therapeutics Ltd.
  • 3. Aeterna Zentaris Inc.
  • 4. Aphios Corporation
  • 5. Artelo Biosciences Inc.
  • 6. AVEO Pharmaceuticals Inc.
  • 7. Boehringer Ingelheim International GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. Fresenius Kabi AG
  • 10. Green Cross Wellbeing Corporation
  • 11. Helsinn Healthcare SA
  • 12. INOVIO Pharmaceuticals Inc.
  • 13. Mankind Pharma Ltd.
  • 14. Merck & Co. Inc.
  • 15. MetaFines Co., Ltd.
  • 16. NeuBase Therapeutics, Inc.
  • 17. NGM Biopharmaceuticals Inc.
  • 18. Ono Pharmaceutical Co., Ltd.
  • 19. Pfizer Inc.
  • 20. Tetra Bio-Pharma

LIST OF FIGURES

  • FIGURE 1. CANCER CACHEXIA MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER CACHEXIA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER CACHEXIA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER CACHEXIA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER CACHEXIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER CACHEXIA MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PROGESTOGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER CACHEXIA MARKET SIZE, BY WEIGHT LOSS STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACY STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. CANCER CACHEXIA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. CANCER CACHEXIA MARKET, FPNV POSITIONING MATRIX, 2023